Serine/Threonine Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or Cell Cycle Checkpoint Kinase or CHEK1 or EC 2.7.11.1) - Pipeline Review, H2 2016

  • ID: 4020189
  • Report
  • 58 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • CanBas Co Ltd
  • Eli Lilly and Company
  • Genentech Inc
  • ProNAi Therapeutics Inc
  • Sareum Holdings Plc
  • Vernalis Plc
  • MORE
Serine/Threonine Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or Cell Cycle Checkpoint Kinase or CHEK1 or EC 2.7.11.1) - Pipeline Review, H2 2016

Summary:

‘Serine/Threonine Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or Cell Cycle Checkpoint Kinase or CHEK1 or EC 2.7.11.1) - Pipeline Review, H2 2016’, provides in depth analysis on Serine/Threonine Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or Cell Cycle Checkpoint Kinase or CHEK1 or EC 2.7.11.1) targeted pipeline therapeutics.

The report provides comprehensive information on the Serine/Threonine Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or Cell Cycle Checkpoint Kinase or CHEK1 or EC 2.7.11.1) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Additionally, the report provides an overview of key players involved in Serine/Threonine Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or Cell Cycle Checkpoint Kinase or CHEK1 or EC 2.7.11.1) targeted therapeutics development and features dormant and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:
Certain sections in the report may be removed or altered based on the availability and relevance of data.
Updated report will be delivered in 48 hours of order confirmation.

Scope:

- The report provides a snapshot of the global therapeutic landscape for Serine/Threonine Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or Cell Cycle Checkpoint Kinase or CHEK1 or EC 2.7.11.1)
- The report reviews Serine/Threonine Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or Cell Cycle Checkpoint Kinase or CHEK1 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Serine/Threonine Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or Cell Cycle Checkpoint Kinase or CHEK1 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Serine/Threonine Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or Cell Cycle Checkpoint Kinase or CHEK1 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Serine/Threonine Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or Cell Cycle Checkpoint Kinase or CHEK1 or EC 2.7.11.1) targeted therapeutics

Reasons to Buy:

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Serine/Threonine Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or Cell Cycle Checkpoint Kinase or CHEK1 or EC 2.7.11.1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Serine/Threonine Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or Cell Cycle Checkpoint Kinase or CHEK1 or EC 2.7.11.1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • CanBas Co Ltd
  • Eli Lilly and Company
  • Genentech Inc
  • ProNAi Therapeutics Inc
  • Sareum Holdings Plc
  • Vernalis Plc
  • MORE
Introduction

Serine/Threonine Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or Cell Cycle Checkpoint Kinase or CHEK1 or EC 2.7.11.1) Overview

Therapeutics Development

Serine/Threonine Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or Cell Cycle Checkpoint Kinase or CHEK1 or EC 2.7.11.1) - Products under Development by Stage of Development

Serine/Threonine Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or Cell Cycle Checkpoint Kinase or CHEK1 or EC 2.7.11.1) - Products under Development by Therapy Area

Serine/Threonine Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or Cell Cycle Checkpoint Kinase or CHEK1 or EC 2.7.11.1) - Products under Development by Indication

Serine/Threonine Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or Cell Cycle Checkpoint Kinase or CHEK1 or EC 2.7.11.1) - Pipeline Products Glance

Late Stage Products

Early Stage Products

Serine/Threonine Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or Cell Cycle Checkpoint Kinase or CHEK1 or EC 2.7.11.1) - Products under Development by Companies

Serine/Threonine Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or Cell Cycle Checkpoint Kinase or CHEK1 or EC 2.7.11.1) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Serine/Threonine Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or Cell Cycle Checkpoint Kinase or CHEK1 or EC 2.7.11.1) - Companies Involved in Therapeutics Development

CanBas Co Ltd

Cascadian Therapeutics Inc

Eli Lilly and Company

Genentech Inc

ProNAi Therapeutics Inc

Sareum Holdings Plc

Vernalis Plc

Serine/Threonine Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or Cell Cycle Checkpoint Kinase or CHEK1 or EC 2.7.11.1) - Drug Profiles

CBP-501 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CCT-244747 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FS-105 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GDC-0575 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ONT-2409 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PNT-737 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

prexasertib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SAR-020106 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Chk1 for Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit CHK1 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

V-158411 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Serine/Threonine Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or Cell Cycle Checkpoint Kinase or CHEK1 or EC 2.7.11.1) - Dormant Projects

Serine/Threonine Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or Cell Cycle Checkpoint Kinase or CHEK1 or EC 2.7.11.1) - Discontinued Products

Serine/Threonine Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or Cell Cycle Checkpoint Kinase or CHEK1 or EC 2.7.11.1) - Featured News & Press Releases

Oct 05, 2016: Lilly To Present New Data on Prexasertib At ESMO 2016

Sep 22, 2016: New triple therapy could boost treatment and prevent relapse in head and neck cancer

May 23, 2016: Clinical Trials of CHK1 Inhibitor CCT245737 to Open at the Royal Marsden Hospital

Apr 19, 2016: Oncothyreon Highlights Novel Checkpoint Kinase 1 Inhibitors at American Association for Cancer Research (AACR) Annual Meeting 2016

Apr 05, 2016: CHK1 inhibitor CCT245737 Approved for Clinical Trials in Cancer Patients

Feb 01, 2016: CHK1 Clinical Trial Application Submissions

Dec 15, 2015: CHK1 Clinical Trial Applications

May 12, 2015: Sareum to Present at BioTrinity 2015

Apr 20, 2015: Lilly Releases Early-Stage Pipeline Data On LY2606368 at AACR Annual Meeting 2015

Apr 17, 2013: CanBas Announces Topline Results From Phase II Trial Of CBP501 In Patients With Non-Small Cell Lung Cancer

Jun 04, 2012: CanBas's CBP501 Meets Primary Endpoint In Phase II Study Of Malignant Pleural Mesothelioma

Jan 05, 2012: CanBas's CBP501 Receives Orphan Drug Designation From FDA For Malignant Mesothelioma

Nov 01, 2011: Canbas Enrolls Last Patient In Phase II Trial Of CBP501 As First-Line Treatment Of Malignant Pleural Mesothelioma

Oct 27, 2011: Canbas Announces Last Patient Enrolled In Phase II Trial Of CBP501 As First-Line Treatment Of Non-Small Cell Lung Cancer

Jan 20, 2010: New Molecules SAR-020106 Increase The Effectiveness Of Certain Cancer Therapies

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Number of Products under Development for, H2 2016

Number of Products under Development by Therapy Area, H2 2016

Number of Products under Development by Indication, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Number of Products under Development by Companies, H2 2016

Products under Development by Companies, H2 2016

Products under Development by Companies, H2 2016 (Contd..1)

Assessment by Monotherapy/Combination Products, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Pipeline by CanBas Co Ltd, H2 2016

Pipeline by Cascadian Therapeutics Inc, H2 2016

Pipeline by Eli Lilly and Company, H2 2016

Pipeline by Genentech Inc, H2 2016

Pipeline by ProNAi Therapeutics Inc, H2 2016

Pipeline by Sareum Holdings Plc, H2 2016

Pipeline by Vernalis Plc, H2 2016

Dormant Projects, H2 2016

Discontinued Products, H2 2016

List of Figures:

Number of Products under Development for, H2 2016

Number of Products under Development by Top 10 Indication, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Assessment by Monotherapy/Combination Products, H2 2016

Number of Products by Stage and Mechanism of Actions, H2 2016

Number of Products by Routes of Administration, H2 2016

Number of Products by Stage and Routes of Administration, H2 2016

Number of Products by Molecule Types, H2 2016

Number of Products by Stage and Molecule Type, H2
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • CanBas Co Ltd
  • Cascadian Therapeutics Inc
  • Eli Lilly and Company
  • Genentech Inc
  • ProNAi Therapeutics Inc
  • Sareum Holdings Plc
  • Vernalis Plc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll